<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women	</title>
	<atom:link href="https://www.novumpr.nl/2019/03/06/gilead-presents-new-data-on-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-and-taf-based-regimens-for-the-treatment-of-hiv-1-in-children-older-adults-and-women/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2019/03/06/gilead-presents-new-data-on-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-and-taf-based-regimens-for-the-treatment-of-hiv-1-in-children-older-adults-and-women/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-presents-new-data-on-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-and-taf-based-regimens-for-the-treatment-of-hiv-1-in-children-older-adults-and-women</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 07 Mar 2019 07:48:11 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
